These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 22842597)

  • 1. Human cytomegalovirus end-organ disease is associated with high or low systemic viral load in preemptively treated solid-organ transplant recipients.
    Gerna G; Lilleri D; Furione M; Castiglioni B; Meloni F; Rampino T; Agozzino M; Arbustini E
    New Microbiol; 2012 Jul; 35(3):279-87. PubMed ID: 22842597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of human cytomegalovirus infection in transplantation: validation of virologic cut-offs for preemptive therapy and immunological cut-offs for protection.
    Gerna G; Lilleri D; Furione M; Baldanti F
    New Microbiol; 2011 Jul; 34(3):229-54. PubMed ID: 21811744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study.
    Gerna G; Baldanti F; Torsellini M; Minoli L; Viganò M; Oggionnis T; Rampino T; Castiglioni B; Goglio A; Colledan M; Mammana C; Nozza F; Daniele L;
    Antivir Ther; 2007; 12(1):63-72. PubMed ID: 17503749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic and local human cytomegalovirus-specific T-cell response in lung transplant recipients.
    Lilleri D; Gerna G; Bruno F; Draghi P; Gabanti E; Fornara C; Meloni F
    New Microbiol; 2013 Jul; 36(3):267-77. PubMed ID: 23912868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients.
    Lilleri D; Baldanti F; Gatti M; Rovida F; Dossena L; De Grazia S; Torsellini M; Gerna G
    J Med Virol; 2004 Jul; 73(3):412-8. PubMed ID: 15170637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human cytomegalovirus-specific CD4+ and CD8+ T cell responses in primary infection of the immunocompetent and the immunocompromised host.
    Lilleri D; Zelini P; Fornara C; Comolli G; Revello MG; Gerna G
    Clin Immunol; 2009 Jun; 131(3):395-403. PubMed ID: 19268633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reconstitution of Human Cytomegalovirus-Specific CD4+ T Cells is Critical for Control of Virus Reactivation in Hematopoietic Stem Cell Transplant Recipients but Does Not Prevent Organ Infection.
    Gabanti E; Lilleri D; Ripamonti F; Bruno F; Zelini P; Furione M; Colombo AA; Alessandrino EP; Gerna G
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2192-2202. PubMed ID: 26260678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells are both required for prevention of HCMV disease in seropositive solid-organ transplant recipients.
    Gabanti E; Bruno F; Lilleri D; Fornara C; Zelini P; Cane I; Migotto C; Sarchi E; Furione M; Gerna G
    PLoS One; 2014; 9(8):e106044. PubMed ID: 25166270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic significance and clinical impact of quantitative assays for diagnosis of human cytomegalovirus infection/disease in immunocompromised patients.
    Gerna G; Percivalle E; Baldanti F; Sarasini A; Zavattoni M; Furione M; Torsellini M; Revello MG
    New Microbiol; 1998 Jul; 21(3):293-308. PubMed ID: 9699213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of HCMV-specific T-cell lines from seropositive solid-organ-transplant recipients for adoptive T-cell therapy.
    Brestrich G; Zwinger S; Roemhild A; Noutsias M; Rohde M; Keeren K; Sawitzki B; Volk HD; Reinke P; Hammer MH
    J Immunother; 2009; 32(9):932-40. PubMed ID: 19816188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring transplant patients for human cytomegalovirus: Diagnostic update.
    Gerna G; Lilleri D
    Herpes; 2006 May; 13(1):4-11. PubMed ID: 16732996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follow-up of 28 HCMV seropositive renal-transplant recipients: comparison of clinical, biological and virological parameters in the groups of treated versus untreated infected patients.
    Kamar N; Mengelle C; Yahyaoui S; Sandres-Sauné K; Durand D; Izopet J; Rostaing L
    J Clin Virol; 2005 May; 33(1):35-42. PubMed ID: 15797363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human cytomegalovirus (HCMV)-specific CD4+ T lymphocyte response in AIDS patients with no past or current HCMV disease following HAART.
    Tamarit A; Alberola J; Mir A; Benet I; Mira JV; Muñoz C; Galindo MJ; Navarro D
    J Clin Virol; 2004 Apr; 29(4):308-14. PubMed ID: 15018860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.
    Baldanti F; Lilleri D; Campanini G; Comolli G; Ridolfo AL; Rusconi S; Gerna G
    J Antimicrob Chemother; 2004 Mar; 53(3):536-9. PubMed ID: 14739146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease.
    Tu W; Potena L; Stepick-Biek P; Liu L; Dionis KY; Luikart H; Fearon WF; Holmes TH; Chin C; Cooke JP; Valantine HA; Mocarski ES; Lewis DB
    Circulation; 2006 Oct; 114(15):1608-15. PubMed ID: 17015794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
    Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A
    Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients.
    Tormo N; Solano C; Benet I; Clari MA; Nieto J; de la Cámara R; López J; López-Aldeguer N; Hernández-Boluda JC; Remigia MJ; Garcia-Noblejas A; Gimeno C; Navarro D
    Bone Marrow Transplant; 2010 Mar; 45(3):543-9. PubMed ID: 19617905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection.
    Lilleri D; Fornara C; Chiesa A; Caldera D; Alessandrino EP; Gerna G
    Haematologica; 2008 Feb; 93(2):248-56. PubMed ID: 18245650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital.
    Fleming T; Dunne J; Crowley B
    J Med Virol; 2010 Mar; 82(3):433-40. PubMed ID: 20087937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CMV-specific T-cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study.
    Sund F; Lidehäll AK; Claesson K; Foss A; Tötterman TH; Korsgren O; Eriksson BM
    Clin Transplant; 2010; 24(3):401-9. PubMed ID: 19222507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.